Gevo Issues Statement on USPTO Reexamination of U.S. Patent 8,101,808
Gevo, Inc. (NASDAQ: GEVO) issues statement regarding U.S. Patent and Trademark Office (USPTO) announcement to grant the Butamax(TM) Advanced Biofuels, LLC (Butamax) Request for Reexamination of Gevo's (http://www.gevo.com/our-business/our-science-and-technology/) GIFT® technology, U.S. Patent 8,101,808.
"Reexaminations are part of the normal course of a (http://www.gevo.com/our-business/intellectual-property/) patent dispute, especially when dealing with valuable technology. This reexamination does not validate patent applications of Butamax or anyone else -- that isn't what reexaminations do. The headline in the Butamax press release is inflammatory and misleading.
Gevo's '808 Patent covers multiple production technologies for higher alcohols in retrofitted ethanol plants. We believe that Butamax is infringing at least one of those technologies. While our claims have been set aside in this most recent USPTO action, Gevo's lawsuit against Butamax for infringing this '808 Patent remains unaffected; the trial is scheduled for July of 2014.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.